Karl Kieburtz

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Medicine, Neurology, Neuroscience +14

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Rachelle S. Doody, Rema Raman, Martin R. Farlow et al. · New England Journal of Medicine · 2013 · 1.2K citations

Medicine, Pharmacology, Pharmacotherapy +17

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

Raymond Scott Turner, Ronald G. Thomas, Suzanne Craft et al. · Neurology · 2015 · 699 citations · Full text

Medicine, Neurology, Neuroscience +15

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

C. Warren Olanow, Karl Kieburtz, Per Odin et al. · The Lancet Neurology · 2013 · 696 citations

Pharmacy, Neurology, Pharmacotherapy +12

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

Kenneth Marek, Sohini Chowdhury, Andrew Siderowf et al. · Annals of Clinical and Translational Neurology · 2018 · 686 citations · Full text

Life Sciences, Neurology, Neuroscience +17